Cancer Vaccine Makers Capitalize On Provenge Fanfare At ASCO
Heading into this year's American Society of Clinical Oncology meeting, beleaguered cancer immunotherapy developers finally have some cause for optimism about potential partnerships and, battle-hardened, they say they are hearty enough to wait for deals to roll in
You may also be interested in...
Fate of IDM’s dendritic cell-based Uvidem and other cancer vaccines remains unclear after $75 million purchase.
Hepatitis C vaccine success validated technology and paved way for the deal.
Despite the lack of innovative drugs highlighted in ASCO's media briefing on its upcoming annual meeting, there is a range of oncology development updates that will be presented - including some surprises